Charcot-Marie-Tooth Disease is estimated to have a global prevalence of 2.6 million worldwide (NINDS). As per DelveInsight, the total Charcot-Marie-Tooth prevalence in the 7MM (the US, EU5, and Japan) was 263,835 in 2020 which is expected to increase in the coming years. Moreover, the estimates suggest that females are prone to get diagnosed with CMTdisease as compared to males.
It is observed that the missed or late diagnosis is a serious concern associated with Charcot-Marie-Tooth Disease; however, it can be due to the heterogeneity of the condition, late age of onset of symptoms, slow and gradual development of symptoms, and so on. Moreover, the lack of curative and approved therapies in the Charcot-Marie-Tooth Disease Market is another serious unmet need.
To fulfill the therapeutics need, some of the key pharmaceutical companies such as PharNext, MedDayPharma, among others are proactively working in the domain; however, the Charcot-Marie-Tooth disease pipeline constitutes only a few therapeutic agents in advanced stages of clinical trials. As per DelveInsight, the Charcot-Marie-Tooth therapy market is expected to surge at a CAGR of 25.42% for the study period 2018–2030, with the USA accounting for the majority of the market share in the 7MM.
Explore more: Key Companies in the Charcot-Marie-Tooth Disease Market